Migalastat
Ended Awarded Last action
- Contract number
- 36C26126F0214
- Awardee
-
Amicus Therapeutics US, LLC UEI KLJFGENKMD89
- Awarding agency
-
Veterans Integrated Service Network 21
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $22,840
Award facts
- Contract value 100% obligated
- $22,839.61 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Philadelphia, PA 19104, USA
Award details come from SAM.gov/FPDS.
About this award
The Department of Veterans Affairs, specifically Veterans Integrated Service Network 21 (VISN 21), awarded a delivery order valued at $22,839.61 to Amicus Therapeutics US, LLC for the supply of Migalastat (Galafold 123 mg) on April 29, 2026. This firm fixed-price delivery order, with an ultimate completion date of May 29, 2026, represents a child order under the parent Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract (36F79724D0185). The contract carries no set-aside designation and specifies performance at a location in Philadelphia, Pennsylvania. Amicus Therapeutics US, LLC, a biopharmaceutical subsidiary specializing in rare genetic disease treatments, serves as the prime contractor with direct performance responsibility and no subcontractor involvement.
Migalastat is an FDA-approved enzyme replacement therapy indicated for the treatment of Fabry disease, a critical medication within the VA healthcare system for supporting veteran care. Amicus Therapeutics has established an extensive procurement history with the VA, having fulfilled over 150 delivery orders across multiple Veterans Integrated Service Networks since March 2021, with individual order values historically ranging from approximately $18,520 to $284,586. The parent FSS contract, valued at $13,024,630 and effective through August 31, 2029, enables various VA regions nationwide to place delivery orders for this specialized pharmaceutical product, with procurement patterns demonstrating both routine supply requirements and emergency pharmacy purchases essential to treating veterans with rare genetic diseases.
Quick answers
Who was awarded contract 36C26126F0214?
36C26126F0214 was awarded to Amicus Therapeutics US, LLC by Veterans Integrated Service Network 21 (Veterans Health Administration) on April 29, 2026.
How much is contract 36C26126F0214 worth?
The government has obligated $22,840 on 36C26126F0214.
Is contract 36C26126F0214 an order under another contract?
Yes. 36C26126F0214 is a delivery order under 36F79724D0185, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C26126F0214 competed?
The extent of competition for 36C26126F0214 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award